AN2 Therapeutics Inc ANTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
-
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
-
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $1.06–1.09
- 52-Week Range
- $0.87–22.13
- Bid/Ask
- $1.05 / $1.08
- Market Cap
- $31.63 Mil
- Volume/Avg
- 175,519 / 605,731
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 36
- Website
- https://www.an2therapeutics.com
Comparables
Valuation
|
Metric
|
ANTX
|
MORF
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.32 | 4.62 | 2.23 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ANTX
MORF
CTNM
Financial Strength
|
Metric
|
ANTX
|
MORF
|
CTNM
|
|---|---|---|---|
Quick Ratio | 10.32 | 23.71 | 58.48 |
Current Ratio | 10.61 | 24.13 | 58.92 |
Interest Coverage | — | — | — |
Quick Ratio
ANTX
MORF
CTNM
Profitability
|
Metric
|
ANTX
|
MORF
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −44.75% | −20.07% | −18.15% |
Return on Equity (Normalized) | −49.61% | −20.72% | −871.68% |
Return on Invested Capital (Normalized) | −49.61% | −24.50% | −892.99% |
Return on Assets
ANTX
MORF
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pyvxglxbdd | Cyrc | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kztfbtbd | Gzbcfh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xhmffwkcc | Yhkqk | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rsgdtgxh | Ymhwmj | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Stychskc | Bpch | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Dgqpgcjy | Yykm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xgmhzczk | Qwsl | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mjmnvyxw | Fvwt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fkdfsrnl | Hmnhvfd | $13.4 Bil | |||
| Incyte Corp
INCY
| Zsspgdw | Ysdrm | $12.7 Bil |
United States